Department of Molecular and Cell Biology, University of California, Berkeley, CA, 94720, USA.
Leibniz-Forschungsinstitut für Molekulare Pharmakologie, 13125, Berlin, Germany.
Curr Opin Pharmacol. 2022 Aug;65:102259. doi: 10.1016/j.coph.2022.102259. Epub 2022 Jun 21.
Blinding diseases that are caused by degeneration of rod and cone photoreceptor cells often spare the rest of the retinal circuit, from bipolar cells, which are directly innervated by photoreceptor cells, to the output ganglion cells that project axons to the brain. A strategy for restoring vision is to introduce light sensitivity to the surviving cells of the retina. One approach is optogenetics, in which surviving cells are virally transfected with a gene encoding a signaling protein that becomes sensitive to light by binding to the biologically available chromophore retinal, the same chromophore that is used by the opsin photo-detectors of rods and cones. A second approach uses photopharmacology, in which a synthetic photoswitch associates with a native or engineered ion channel or receptor. We review these approaches and look ahead to the next generation of advances that could reconstitute core aspects of natural vision.
由视杆和视锥光感受器细胞变性引起的致盲性疾病通常会保留视网膜回路的其余部分,包括直接由光感受器细胞支配的双极细胞,以及投射轴突到大脑的输出节细胞。恢复视力的策略是为视网膜的存活细胞引入光敏性。一种方法是光遗传学,其中通过病毒转染将编码信号蛋白的基因引入存活细胞,该信号蛋白通过与生物可利用的视黄醛结合而对光敏感,视黄醛是与视杆和视锥的视蛋白光探测器一起使用的相同的视黄醛。第二种方法使用光药理学,其中合成光开关与天然或工程离子通道或受体结合。我们回顾了这些方法,并展望了下一代可能重建自然视觉核心方面的进展。